Remote Digital Deployment of a Validated Psychosis Screener in Parkinson’s Disease: Real-World Feasibility and Screening Yield
Objective: To evaluate rapid remote deployment of the Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP) and assess whether screening identifies unmet need for clinician…Lack of Association Between Polygenic Risk Scores for Parkinson’s Disease and Age at Onset, Freezing of Gait, or Psychosis
Objective: To evaluate whether the polygenic risk scores of Parkinson’s disease (PD-PRS) is associated with age at disease onset (AAO), freezing of gait (FOG) or…Nocturnal Blood Pressure Non-Dipping as an Autonomic Biomarker of Psychosis and Movement Disorder Severity in Pediatric Epilepsy
Objective: To investigate the association between 24-hour ambulatory blood pressure monitoring (ABPM) patterns, particularly nocturnal non-dipping, and psychosis severity, movement disorder burden, and non-motor symptoms…Psychosis in Parkinson’s Disease Patients Treated with Continuous Subcutaneous Foslevodopa/Foscarbidopa: A Real-World Observational Study.
Objective: To assess the incidence and timing of psychosis (hallucinations and delusions) in Parkinson’s disease patients receiving continuous subcutaneous infusion of foslevodopa/foscarbidopa (CSFLI). Background: CSFLI…A Case of NUS1 Spectrum Disorder with Adult-Onset Psychosis
Objective: To report a novel case of NUS1 spectrum with childhood-onset abnormal movements and adult-onset psychiatric manifestations. Background: The NUS1 gene is associated with developmental…Psychotic Symptoms and Cognitive Impairment in Huntington’s Disease
Objective: To investigate the clinical and cognitive correlates of psychotic symptoms in patients with Huntington’s disease (HD). Background: Psychiatric manifestations are common in HD, but…Duration of Illness and Response to Pimavanserin in Parkinson’s Disease Psychosis: Post-Hoc Analysis of Clinical Trial Data
Objective: To examine individual responses to pimavanserin in patients with Parkinson’s disease psychosis (PDP) initiating treatment <6 vs ≥6 months and <12 vs ≥12 months…Atypical Psychosis in Parkinson Disease: A Retrospective Study on 24-Hour Continuous Subcutaneous Infusion Foslevodopa/Foscarbidopa Therapy
Objective: This study aims to identify clinical predictors of continuous subcutaneous infusion (CSCI)-induced psychosis to understand its potential mechanisms and evaluate predictive measures for its…Demographic Features, QTc Interval and Psychosis in Military Veterans with Parkinson’s disease (PD)
Objective: To compare certain key demographic features and QTc intervals in groups of PD military Veterans with and without psychosis. Background: Psychosis is a disabling…Refining the International Parkinson and Movement Disorder Society Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS): Cognitive Interview Results from an International Study
Objective: To assess the face and content validity of the International Parkinson and Movement Disorder Society Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS), a new under-developing Clinical…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 14
- Next Page »